What Are the 2027 Medicare Lab Fee Schedule Changes for Urgent Care?
As of September 2026, CMS has released preliminary 2027 Clinical Laboratory Fee Schedule (CLFS) rates that show an average 16% reduction in Medicare reimbursement for clinical lab tests. The cuts are based on private payor rate data collected under the Protecting Access to Medicare Act (PAMA) and affect roughly 1,171 of the 1,528 lab test codes with reported data. For urgent care centers that bill in-house lab tests to Medicare, this means lower payments on common diagnostics starting January 1, 2027, with reductions capped at 15% per year through 2029.
Which tests are affected: Chemistry codes face an average 16% cut, microbiology codes face 19.3%, and immunology codes face 19.3%. These categories cover rapid strep, urinalysis, basic metabolic panels, and flu testing that urgent care centers perform daily.
When the cuts take effect: CMS will finalize rates in November 2026, with new payment amounts effective January 1, 2027. The phase-in provision limits any single test to a maximum 15% reduction per year through 2029.
What urgent care clinics should do now: Run a revenue analysis on your current Medicare lab mix, identify which in-house tests will be hit hardest, and evaluate whether your billing workflow captures every allowable modifier and code to protect remaining reimbursement.
What CMS Announced on September 21, 2026
On September 21, 2026, CMS published preliminary Calendar Year 2027 Clinical Laboratory Fee Schedule (CLFS) payment rates. This release represents the second full data collection and reporting cycle under the Protecting Access to Medicare Act of 2014 (PAMA), and it is the first time since 2018 that CMS has recalculated lab payment rates using fresh private payor data at this scale.
The numbers tell a clear story. Of the approximately 1,528 lab test codes with a weighted median from private payor data, 1,171 codes will see lower Medicare reimbursement, 169 codes remain unchanged, and 186 codes actually carry a higher weighted median than the current CLFS rate. On average across all affected tests, the preliminary rates sit roughly 16% below the current 2026 CLFS levels.
CMS arrived at these preliminary figures by collecting private payor rate data from 6,411 laboratories during the January through June 2025 data collection window. After applying quality controls to remove duplicate and outlier records, CMS calculated weighted median private payor rates for each test code. The result shows that Medicare has been paying approximately 16% more for laboratory services than private payors, which CMS estimates represents roughly $1 billion annually in overpayment. The full methodology and data are available in the CMS preliminary CLFS fact sheet.
These are preliminary rates, not final. CMS has opened a 30-day public comment window and plans to publish final CY 2027 CLFS rates in November 2026, with the new payment amounts taking effect January 1, 2027. However, preliminary rates historically track closely to final rates in prior PAMA cycles, so clinics should plan around these numbers rather than hoping for significant upward revisions.
Does This Apply to My Urgent Care Clinic?
If your urgent care center performs in-house lab testing and bills those tests to Medicare Part B, these rate changes apply directly to you. The CLFS governs payment for clinical diagnostic laboratory tests including rapid strep tests (CPT 87880), urinalysis (CPT 81001 through 81003), complete blood counts, influenza and COVID-19 rapid panels, basic metabolic panels, and blood glucose testing. These are the bread-and-butter diagnostics that urgent care providers run multiple times per day. If your clinic also bills E/M codes like CPT 99281 alongside those lab tests on the same encounter, the combined reimbursement per visit is what matters, and the lab side of that equation is about to shrink.
The clinics with the most exposure are those with a higher Medicare patient mix and a higher volume of in-house testing. If your clinic serves an area with a significant Medicare-age population, or if you have invested in CLIA-waived point-of-care testing equipment specifically to capture lab revenue, these cuts will compress that revenue starting in January.
In our experience matching providers with billing partners, the clinics that struggle most with fee schedule changes are the ones that do not run a cost-per-test analysis before the cuts take effect. They absorb the lower reimbursement without knowing which tests are still profitable and which are now losing money on reagent and staff time alone. The rate reductions are not uniform. Chemistry tests face a different average cut than microbiology or immunology tests, and individual codes within those categories vary even more.
Urgent care centers that send lab work to reference laboratories rather than performing tests in-house will see this differently. The reference lab absorbs the reimbursement cut, not the urgent care clinic. However, if the reference lab raises its processing fees to compensate for lower Medicare payments, some of that cost may flow back to the clinic through renegotiated contracts.
Why Lab Rates Are Dropping Now
These cuts are not a policy decision made in isolation. They are the result of a data reporting cycle that Congress has been delaying for years. PAMA was signed into law in 2014. The first round of data collection happened in 2016, with reporting in 2017 and rates taking effect in 2018. The second round was supposed to follow on a three-year cycle, but Congress repeatedly postponed it through a series of continuing resolutions and appropriations acts.
The Consolidated Appropriations Act, 2026 finally set the timeline for this second reporting cycle: data collection from January through June 2025, reporting from May through July 2026, and preliminary rates published in September 2026. What makes this round different from 2018 is the scale of participation. The number of reporting laboratories jumped from 1,942 in 2017 to 6,411 in 2026, a 230% increase. Hospital lab participation increased by over 4,000%, and physician office labs nearly tripled.
That broader participation means the weighted median private payor rates are based on a much larger and more representative data set. And the data shows a consistent pattern: private payors have been paying significantly less than Medicare for the same tests. CMS views this as Medicare overpaying, and PAMA requires CMS to align its rates with the market.
For urgent care operators, the takeaway is simple. This is not a one-time adjustment. PAMA requires ongoing data reporting and rate recalculation. The 2027 rates will be the baseline for the next cycle. If private payor rates continue trending downward, Medicare lab payments will follow. Combined with the proposed modifier 25 payment cut for 2027, urgent care clinics face pressure on two of their highest-volume billing lines simultaneously.
How Much Will Urgent Care Lab Reimbursement Drop?
The reductions vary by test category. CMS published category-level summaries that give urgent care clinics a clear picture of where the steepest cuts fall. The table below shows the average potential rate change by the lab test categories most relevant to urgent care operations.
| Test Category | Codes Affected | Average Rate Change |
| Chemistry | 387 | -16% |
| Microbiology | 224 | -19.3% |
| Immunology | 205 | -19.3% |
| Molecular Pathology | 211 | -22% |
| Genomic Sequencing | 42 | -23% |
| Proprietary Lab Analysis | 151 | -2.4% |
For a typical urgent care clinic running rapid strep, urinalysis, CBC, flu panels, and blood glucose tests on Medicare patients, the chemistry and microbiology categories represent the highest volume exposure. A clinic performing 30 Medicare lab tests per day across these categories could see a revenue reduction of $15,000 to $25,000 annually depending on test mix and current reimbursement levels.
The phase-in provision under the Consolidated Appropriations Act, 2026 limits reductions to 15% per year from 2027 through 2029. That means if a specific test is calculated to drop 25% based on the weighted median, the actual cut in 2027 would be capped at 15%, with the remaining reduction phased in over the following two years. This does not eliminate the impact. It spreads it across a three-year window, which gives clinics time to adjust operations but does not reverse the trend.
Providers often come to us after a fee schedule change has already compressed their margins on specific service lines. The clinics that fare best are the ones that model the impact before it arrives and make billing adjustments proactively rather than reactively.
What Should Urgent Care Clinics Do Before January 2027?
The window between now and January 1, 2027 is the preparation period. Final rates publish in November, and the changes take effect eight weeks later. These are the steps every urgent care clinic billing Medicare lab tests should take.
1. Pull your Medicare lab claims data for the past 12 months. Identify every CLFS code your clinic has billed, the volume per code, and the reimbursement received. This gives you the baseline to calculate the financial impact when CMS publishes final rates.
2. Run a cost-per-test analysis on your highest-volume in-house tests. Factor in reagent cost, equipment depreciation, quality control supplies, and the staff time required to run and document each test. Compare that cost to the preliminary 2027 rate. If a test costs more to run than Medicare will pay, it needs a workflow or sourcing change.
3. Review your payer mix. The CLFS changes apply to Medicare Part B. Commercial payers negotiate their own lab rates, and some Medicaid programs reference the CLFS as a benchmark. Know what percentage of your lab volume is Medicare, and use that to estimate total revenue impact rather than applying the average cut across all payers.
4. Audit your lab billing for missed charges and coding gaps. When reimbursement drops per test, capturing every legitimate charge becomes more important. Common missed items include handling fees for specimens sent to reference labs, miscoded panels versus individual tests, and tests documented in the chart but never entered into the billing system.
5. Evaluate your reference lab contracts. If you send tests to an outside lab, the CLFS cut hits their revenue, and they may renegotiate your contract terms. Get ahead of this by reviewing your current agreement and understanding which tests are most affected.
6. Submit comments to CMS during the 30-day window. CMS is accepting public comments on the preliminary rates at CLFS_Annual_Public_Meeting@cms.hhs.gov. Industry organizations like the Urgent Care Association and ACLA are expected to submit formal comments. Individual clinics can also provide feedback on specific codes where they believe the weighted median does not reflect true market conditions.
7. Brief your billing team on the timeline. Final rates publish in November 2026. Fee schedules, expected reimbursement tables, and any payer-specific adjustments need to be updated before the first claims go out in January. Make sure your team is also current on all other October 1 code changes, including any updates that affect after-hours billing under CPT 99051 and other codes your clinic bills regularly. A billing partner familiar with the CLFS structure can handle this transition without disrupting your revenue cycle.
Across the billing companies we vet, the ones that protect urgent care revenue best are the ones that build fee schedule changes into their workflow before the effective date. If you want a billing partner that stays ahead of CLFS updates and catches every billable test, we can match you with one.
Common Mistakes When Lab Rates Change
Fee schedule transitions create billing errors because clinics often react too slowly or overcorrect. These are the patterns we see most frequently when reimbursement shifts on a major service line.
Applying the average cut uniformly across all tests. The 16% average is a weighted figure across all categories. Individual codes vary. Some tests will see cuts closer to 5%, while others in the microbiology and immunology categories may hit the 15% annual cap. Making financial projections based on the average rather than reviewing code-level data leads to inaccurate budgets.
Assuming commercial rates will follow Medicare. The CLFS rates are derived from private payor data, but that does not mean commercial payers will automatically lower their contracted rates to match the new CLFS. Some commercial contracts reference the CLFS as a benchmark, and those contracts may trigger automatic adjustments. Others do not. Review each payer contract individually.
Dropping in-house testing without running the numbers. Some clinics will consider eliminating in-house labs entirely and sending everything to a reference lab. This can work financially for low-volume tests, but high-volume point-of-care tests like rapid strep and urinalysis typically remain profitable even at reduced rates because the per-test cost is low. The decision should be driven by a per-code cost analysis, not a blanket reaction to the headline cut.
Ignoring the phase-in structure. The 15%-per-year cap means some tests will not reach their final reduced rate until 2029. Clinics that plan only for the 2027 cut and stop there will be surprised by additional reductions in 2028 and 2029. Build a three-year model, not a one-year adjustment.
Failing to update fee schedules on time. Claims submitted after January 1, 2027 with outdated expected reimbursement tables will create reconciliation problems. If your billing system uses expected payment amounts to flag underpayments, those thresholds need to reflect the new CLFS rates or you will generate false alerts on every Medicare lab claim.
In-House Billing vs. Outsourced Billing for Lab Claims
Lab billing is one of the areas where the gap between in-house and outsourced billing performance shows up most clearly. Lab claims are high-volume, low-dollar transactions that require precise code selection, correct modifier usage, and tight follow-up on underpayments. When reimbursement drops, the margin for error shrinks. This is especially true when lab rate cuts arrive at the same time as other reimbursement pressures like the 2027 modifier 25 payment reduction, which compounds the revenue squeeze on same-day procedure-plus-lab encounters.
A billing company that specializes in urgent care understands the CLFS structure, tracks quarterly HCPCS updates that affect lab codes, and monitors payer-specific lab billing rules that vary between Medicare, Medicaid, and commercial plans. In-house billing teams at smaller urgent care clinics often lack the bandwidth to track fee schedule changes across multiple payers while also managing E/M coding, modifier 25 compliance, and denial follow-up.
The question we hear constantly from practice managers is whether outsourcing lab billing specifically, rather than the entire revenue cycle, makes financial sense. The answer depends on volume. If your clinic runs fewer than 20 Medicare lab tests per day, a dedicated lab billing carve-out may not justify the cost. If you run 50 or more, the coding precision and denial recovery that a specialized billing partner provides often pays for itself in recovered revenue that an in-house team misses.
Regardless of whether billing is handled in-house or outsourced, the immediate action item is the same: get the preliminary CLFS data, map it to your test volume, and build a financial model that accounts for the phase-in through 2029.
Frequently Asked Questions
CMS released preliminary rates on September 21, 2026. Final rates will be published in November 2026. The new CLFS payment amounts take effect January 1, 2027, and apply to all claims for clinical diagnostic laboratory tests with dates of service on or after that date.
The average potential reduction across all codes with private payor data is approximately 16%. However, the Consolidated Appropriations Act, 2026 caps actual reductions at 15% per year from 2027 through 2029. Individual codes may see cuts ranging from less than 5% to the full 15% annual cap depending on how far their current rate exceeds the weighted median.
The Protecting Access to Medicare Act of 2014 (PAMA) changed how Medicare sets lab test payment rates. Instead of using historical fee schedules, PAMA requires CMS to base CLFS rates on the weighted median of private payor rates reported by qualifying laboratories. This market-based approach means Medicare lab rates now track what commercial payers actually pay for the same tests.
Chemistry tests (including blood glucose, basic metabolic panels, and lipid panels) face an average 16% cut. Microbiology tests (including cultures and rapid strep) face 19.3%. Immunology tests (including flu and COVID rapid panels that fall under immunology codes) face 19.3%. The exact impact per code depends on the individual weighted median calculated from reported data.
Not automatically. The CLFS applies to Medicare Part B. Commercial payer rates are set through individual contracts between the payer and the laboratory or provider. However, some commercial and Medicaid contracts reference the CLFS as a benchmark, and rate changes in those contracts may follow. Review each payer contract to determine whether a CLFS reference clause exists.
Yes. CMS has opened a 30-day public comment window following the September 21 release. Comments can be submitted electronically to CLFS_Annual_Public_Meeting@cms.hhs.gov. CMS will consider these comments before publishing final rates in November 2026. Industry organizations and individual providers may both submit feedback.
Not necessarily. The decision depends on your per-test cost, test volume, and payer mix. High-volume point-of-care tests like rapid strep and urinalysis typically remain profitable even at reduced rates because reagent and labor costs per test are low. Run a code-level cost analysis before making operational changes to your lab workflow.
Next Steps
Review the full CMS fact sheet and preliminary CLFS rate data on the CMS Clinical Laboratory Fee Schedule page. For more on how fee schedule changes affect urgent care billing, read our guide on the 2027 modifier 25 payment cut and how it affects urgent care.
If you are evaluating whether your current billing setup can handle the transition, a billing partner matched through Urgent Care Bill Co can run the cost analysis, update your fee schedules, and ensure every lab claim is coded correctly under the new rates.
The 2027 CLFS rate cuts are confirmed. The question is whether your billing workflow is ready. Get matched with a billing company that specializes in urgent care lab billing and knows how to protect your reimbursement through fee schedule transitions.
